drugset / Trial / NCT01860989

A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection

NCT01860989

Phase 2 Completed 11 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with acute P. falciparum infection after single dose with KAE609 at 75 mg, 150mg, 225mg and 300mg/day

Timeline

Start
2013-07
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject cipargamin Small molecule 75 mg
Subject cipargamin Small molecule 150 mg
Subject cipargamin Small molecule 225 mg
Subject cipargamin Small molecule 300 mg

Indications

No indication recorded.